Form 8-K - Current report:
SEC Accession No. 0001213900-26-063481
Filing Date
2026-06-01
Accepted
2026-06-01 16:01:27
Documents
12
Period of Report
2026-05-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0292876-8k_oruka.htm   iXBRL 8-K 27007
2 FIRST AMENDMENT TO IL-23 LICENSE AGREEMENT, DATED MAY 29, 2026 ea029287601ex10-1.htm EX-10.1 26062
  Complete submission text file 0001213900-26-063481.txt   224551

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE orka-20260529.xsd EX-101.SCH 3011
4 XBRL LABEL FILE orka-20260529_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE orka-20260529_pre.xml EX-101.PRE 22356
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0292876-8k_oruka_htm.xml XML 3206
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 261050391
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)